Virus-like particles as preventive and therapeutic cancer vaccines

AL Tornesello, M Tagliamonte, FM Buonaguro… - Vaccines, 2022 - mdpi.com
Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native
virus structure without being infectious. VLPs, similarly to wild type viruses, are able to …

Stress-induced Epstein-Barr virus reactivation

DG Sausen, MS Bhutta, ES Gallo, H Dahari… - Biomolecules, 2021 - mdpi.com
Epstein-Barr virus (EBV) is typically found in a latent, asymptomatic state in
immunocompetent individuals. Perturbations of the host immune system can stimulate viral …

Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates

YF Kang, C Sun, Z Zhuang, RY Yuan, Q Zheng, JP Li… - ACS …, 2021 - ACS Publications
The coronavirus disease pandemic of 2019 (COVID-19) caused by the novel SARS-CoV-2
coronavirus resulted in economic losses and threatened human health worldwide. The …

Urgency and necessity of Epstein-Barr virus prophylactic vaccines

L Zhong, C Krummenacher, W Zhang, J Hong, Q Feng… - npj Vaccines, 2022 - nature.com
Abstract Epstein-Barr virus (EBV), a γ-herpesvirus, is the first identified oncogenic virus,
which establishes permanent infection in humans. EBV causes infectious mononucleosis …

Virus-like particle-templated silica-adjuvanted nanovaccines with enhanced humoral and cellular immunity

M Li, Z Liang, C Chen, G Yu, Z Yao, Y Guo, L Zhang… - ACS …, 2022 - ACS Publications
Virus-like particles (VLPs) are self-assembled viral proteins that represent a superior form of
antigens in vaccine formulations. To enhance immunogenicity, adjuvants, especially the …

Epitopes and mimotopes identification using phage display for vaccine development against infectious pathogens

M Palma - Vaccines, 2023 - mdpi.com
Traditional vaccines use inactivated or weakened forms of pathogens which could have side
effects and inadequate immune responses. To overcome these challenges, phage display …

The status and prospects of Epstein–Barr virus prophylactic vaccine development

C Sun, X Chen, Y Kang, M Zeng - Frontiers in Immunology, 2021 - frontiersin.org
Epstein–Barr virus (EBV) is a human herpesvirus that is common among the global
population, causing an enormous disease burden. EBV can directly cause infectious …

[HTML][HTML] Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy

J Hu, Y Li, H Li, F Shi, L Xie, L Zhao, M Tang, X Luo… - Theranostics, 2020 - ncbi.nlm.nih.gov
Generating oxidative stress is a critical mechanism by which host cells defend against
infection by pathogenic microorganisms. Radiation resistance is a critical problem in …

The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS

JW Li, C Deng, XY Zhou, R Deng - Heliyon, 2024 - cell.com
Abstract EBV positive Diffuse Large B-cell lymphoma, not otherwise specified (EBV+ DLBCL-
NOS) referred to DLBCL with expression of EBV encoded RNA in tumor nucleus. EBV+ …

Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine

V Jean-Pierre, J Lupo, M Buisson, P Morand… - Frontiers in …, 2021 - frontiersin.org
Epstein-Barr virus (EBV) is one of the most widespread viruses in the world; more than 90%
of the planet's adult population is infected. Symptomatic primary infection by this …